The Medical Cold Plasma Market is segmented by device type and technology, revealing a landscape where handheld and bench-top devices cater to different clinical settings, and non-thermal plasma technology remains the dominant approach. According to the Wise Guy Reports analysis, understanding these segments is crucial for grasping the market's operational dynamics and the factors driving innovation.

By device type, handheld devices and bench-top devices represent the largest and most dynamic segments. Handheld devices are favored for their portability, ease of use, and suitability for outpatient and point-of-care applications. These compact, user-friendly devices allow clinicians to deliver cold plasma therapy directly to wound sites, skin lesions, or surgical incisions with precision and control. Their portability makes them ideal for use in clinics, ambulatory surgical centers, and even home care settings. The demand for handheld devices is driven by the growing preference for minimally invasive, office-based procedures and the need for accessible treatment options for chronic wounds and skin conditions.

Bench-top devices offer enhanced functionality and are designed for use in clinical environments such as hospitals and specialized treatment centers. These devices typically provide higher power output, more precise control over plasma parameters, and the ability to treat larger areas. They are often used in research settings and for more complex applications, such as cancer treatment and advanced wound care. Bench-top devices are preferred in academic research institutions and large hospitals where advanced capabilities and data collection are essential.

Room-sized devices represent a smaller but important segment, used in specialized facilities for large-scale sterilization or for treating patients requiring whole-body or extensive surface exposure. Their adoption is more limited due to cost and infrastructure requirements.

By technology, non-thermal plasma is the dominant segment, accounting for the majority of the market. Non-thermal plasma operates at room temperature, making it safe for contact with biological tissues. This technology generates a delicate balance of reactive species that can kill pathogens, promote cell growth, and modulate immune responses without causing thermal damage. Its safety profile and versatility have made it the preferred choice for nearly all medical applications. Thermal plasma, while effective for sterilization, is less commonly used in direct patient contact due to its high temperature. Its applications are primarily limited to sterilizing medical instruments and surfaces.

The growth of both device types and technologies is driven by ongoing innovation. Companies like Apyx Medical, PlasmaTreat GmbH, and Henniker Plasma are continuously developing new platforms. In March 2025, Apyx Medical announced a strategic partnership with Cavitation Technologies to co-develop next-generation cold plasma surgical devices. In June 2025, PlasmaTreat GmbH completed the acquisition of Advanced Plasma Biotech to broaden its portfolio of medical-grade cold plasma platforms. In May 2025, Henniker Plasma secured a major contract to supply its atmospheric cold plasma systems to a large regional hospital network for wound care and sterilization. As technology continues to advance, the market is expected to see the emergence of even more sophisticated, connected, and user-friendly devices, further expanding the reach of cold plasma therapy.